404 related articles for article (PubMed ID: 25732263)
1. Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis.
Wang Z; Qiao D; Lu Y; Curtis D; Wen X; Yao Y; Zhao H
Oncologist; 2015 Apr; 20(4):440-9. PubMed ID: 25732263
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Jakob T; Tesfamariam YM; Macherey S; Kuhr K; Adams A; Monsef I; Heidenreich A; Skoetz N
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013020. PubMed ID: 33270906
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates in multiple myeloma: an updated network meta-analysis.
Mhaskar R; Kumar A; Miladinovic B; Djulbegovic B
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD003188. PubMed ID: 29253322
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.
Zheng GZ; Chang B; Lin FX; Xie D; Hu QX; Yu GY; Du SX; Li XD
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27430483
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials.
Machado M; Cruz LS; Tannus G; Fonseca M
Clin Ther; 2009 May; 31(5):962-79. PubMed ID: 19539097
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
9. Which Bone-Modifying Agent is Associated with Better Outcomes in Patients with Skeletal Metastases from Lung Cancer? A Systematic Review and Network Meta-analysis.
Bozzo A; Deng J; Abbas U; Bhasin R; Deodat M; Wariach S; Sanger S; Axelrod D; Masrouha K; Turcotte R; Wilson D; Ghert M
Clin Orthop Relat Res; 2021 Sep; 479(9):2047-2057. PubMed ID: 33835092
[TBL] [Abstract][Full Text] [Related]
10. Zoledronate for metastatic bone disease and pain: a meta-analysis of randomized clinical trials.
Zhu M; Liang R; Pan LH; Huang B; Qian W; Zhong JH; Zheng WW; Li CL
Pain Med; 2013 Feb; 14(2):257-64. PubMed ID: 23279447
[TBL] [Abstract][Full Text] [Related]
11. Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials.
LeVasseur N; Clemons M; Hutton B; Shorr R; Jacobs C
Cancer Treat Rev; 2016 Nov; 50():183-193. PubMed ID: 27716496
[TBL] [Abstract][Full Text] [Related]
12. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
Stopeck AT; Lipton A; Body JJ; Steger GG; Tonkin K; de Boer RH; Lichinitser M; Fujiwara Y; Yardley DA; Viniegra M; Fan M; Jiang Q; Dansey R; Jun S; Braun A
J Clin Oncol; 2010 Dec; 28(35):5132-9. PubMed ID: 21060033
[TBL] [Abstract][Full Text] [Related]
13. De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis.
Awan AA; Hutton B; Hilton J; Mazzarello S; Van Poznak C; Vandermeer L; Bota B; Stober C; Sienkiewicz M; Fergusson D; Shorr R; Clemons M
Breast Cancer Res Treat; 2019 Aug; 176(3):507-517. PubMed ID: 31079283
[TBL] [Abstract][Full Text] [Related]
14. Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours.
Ford J; Cummins E; Sharma P; Elders A; Stewart F; Johnston R; Royle P; Jones R; Mulatero C; Todd R; Mowatt G
Health Technol Assess; 2013 Jul; 17(29):1-386. PubMed ID: 23870108
[TBL] [Abstract][Full Text] [Related]
15. Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonate therapy in bone metastases from solid tumors population.
Bhowmik D; Song X; Intorcia M; Gray S; Shi N
Curr Med Res Opin; 2019 Mar; 35(3):513-523. PubMed ID: 30286662
[TBL] [Abstract][Full Text] [Related]
16. Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
Murphy L; McCarthy J; McCrate F; Laing K; Powell E; Seal M; Edwards S
Support Care Cancer; 2013 Jun; 21(6):1557-60. PubMed ID: 23334521
[TBL] [Abstract][Full Text] [Related]
17. Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics.
Lipton A; Fizazi K; Stopeck AT; Henry DH; Smith MR; Shore N; Martin M; Vadhan-Raj S; Brown JE; Richardson GE; Saad F; Yardley DA; Zhou K; Balakumaran A; Braun A
Eur J Cancer; 2016 Jan; 53():75-83. PubMed ID: 26693901
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
19. Analysis of denosumab on skeletal-related events in patients with advanced breast cancer.
Bink KF
Clin J Oncol Nurs; 2015 Oct; 19(5):E108-14. PubMed ID: 26414586
[TBL] [Abstract][Full Text] [Related]
20. Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis.
Ding X; Fan Y; Ma F; Li Q; Wang J; Zhang P; Yuan P; Xu B
Breast; 2012 Aug; 21(4):544-9. PubMed ID: 22627092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
